Sinco Pharma Proposes 20% Issuance Mandate, 10% Share Buyback and HK$3.40 Million Final Dividend

Bulletin Express04-20

Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items:

1. Capital Mandates • Issuance Mandate: Directors seek authority to allot and deal with up to 20% of issued shares, equivalent to 406.58 million shares based on the current 2.03 billion share capital. • Repurchase Mandate: The Board requests approval to buy back up to 10% of issued shares, or 203.29 million shares. Shares repurchased may be added to the issuance mandate if the extension resolution is approved.

2. Board Composition • Independent non-executive directors Wang Qing, Bai Zhizhong and Lau Ying Kit are standing for re-election. • The Nomination Committee confirmed their independence and satisfactory performance, with Wang Qing’s tenure exceeding nine years requiring a separate vote.

3. Dividend Proposal • A final dividend of HK0.167 cents per share (total HK$3.40 million) for FY2025 is recommended. Key dates: – Ex-dividend date: 19 May 2026 – Record date: 26 May 2026 – Payment date: on or around 4 June 2026

4. Key Timetable for Shareholders • Transfer books close 12–15 May 2026 to determine AGM voting eligibility; deadline for lodging transfers is 11 May 2026 at 16:30. • Books close again 21–26 May 2026 for dividend entitlement; transfer deadline is 20 May 2026 at 16:30. • Proxy forms must reach Computershare Hong Kong Investor Services by 13 May 2026 at 10:00.

All AGM resolutions will be decided by poll in accordance with Hong Kong Listing Rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121220588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-20 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121220588","market":"hk","top_or_hot":-1,"title":"Sinco Pharma Proposes 20% Issuance Mandate, 10% Share Buyback and HK$3.40 Million Final Dividend","media":"Bulletin Express","content":"<p>Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items:</p>\n<p>1. Capital Mandates  \n   • Issuance Mandate: Directors seek authority to allot and deal with up to 20% of issued shares, equivalent to 406.58 million shares based on the current 2.03 billion share capital.  \n   • Repurchase Mandate: The Board requests approval to buy back up to 10% of issued shares, or 203.29 million shares. Shares repurchased may be added to the issuance mandate if the extension resolution is approved.</p>\n<p>2. Board Composition  \n   • Independent non-executive directors Wang Qing, Bai Zhizhong and Lau Ying Kit are standing for re-election.  \n   • The Nomination Committee confirmed their independence and satisfactory performance, with Wang Qing’s tenure exceeding nine years requiring a separate vote.</p>\n<p>3. Dividend Proposal  \n   • A final dividend of HK0.167 cents per share (total HK$3.40 million) for FY2025 is recommended. Key dates:  \n     – Ex-dividend date: 19 May 2026  \n     – Record date: 26 May 2026  \n     – Payment date: on or around 4 June 2026</p>\n<p>4. Key Timetable for Shareholders  \n   • Transfer books close 12–15 May 2026 to determine AGM voting eligibility; deadline for lodging transfers is 11 May 2026 at 16:30.  \n   • Books close again 21–26 May 2026 for dividend entitlement; transfer deadline is 20 May 2026 at 16:30.  \n   • Proxy forms must reach Computershare Hong Kong Investor Services by 13 May 2026 at 10:00.</p>\n<p>All AGM resolutions will be decided by poll in accordance with Hong Kong Listing Rules.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinco Pharma Proposes 20% Issuance Mandate, 10% Share Buyback and HK$3.40 Million Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinco Pharma Proposes 20% Issuance Mandate, 10% Share Buyback and HK$3.40 Million Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-20 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items:</p>\n<p>1. Capital Mandates  \n   • Issuance Mandate: Directors seek authority to allot and deal with up to 20% of issued shares, equivalent to 406.58 million shares based on the current 2.03 billion share capital.  \n   • Repurchase Mandate: The Board requests approval to buy back up to 10% of issued shares, or 203.29 million shares. Shares repurchased may be added to the issuance mandate if the extension resolution is approved.</p>\n<p>2. Board Composition  \n   • Independent non-executive directors Wang Qing, Bai Zhizhong and Lau Ying Kit are standing for re-election.  \n   • The Nomination Committee confirmed their independence and satisfactory performance, with Wang Qing’s tenure exceeding nine years requiring a separate vote.</p>\n<p>3. Dividend Proposal  \n   • A final dividend of HK0.167 cents per share (total HK$3.40 million) for FY2025 is recommended. Key dates:  \n     – Ex-dividend date: 19 May 2026  \n     – Record date: 26 May 2026  \n     – Payment date: on or around 4 June 2026</p>\n<p>4. Key Timetable for Shareholders  \n   • Transfer books close 12–15 May 2026 to determine AGM voting eligibility; deadline for lodging transfers is 11 May 2026 at 16:30.  \n   • Books close again 21–26 May 2026 for dividend entitlement; transfer deadline is 20 May 2026 at 16:30.  \n   • Proxy forms must reach Computershare Hong Kong Investor Services by 13 May 2026 at 10:00.</p>\n<p>All AGM resolutions will be decided by poll in accordance with Hong Kong Listing Rules.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1121220588","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121220588","pubTimestamp":1776684210,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items: 1....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06833":"兴科蓉医药"},"translate_title":"新科制药建议20%发行授权、10%股份购回及340万港元末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"Sinco Pharmaceuticals Holdings Limited (“Sinco Pharma”) has issued a circular convening its Annual General Meeting (AGM) for 15 May 2026 in Chengdu, where shareholders will vote on four key items:\n1. Capital Mandates  \n   • Issuance Mandate: Directors seek authority to allot and deal with up to 20% of issued shares, equivalent to 406.58 million shares based on the current 2.03 billion share capital.  \n   • Repurchase Mandate: The Board requests approval to buy back up to 10% of issued shares, or 203.29 million shares. Shares repurchased may be added to the issuance mandate if the extension resolution is approved.\n2. Board Composition  \n   • Independent non-executive directors Wang Qing, Bai Zhizhong and Lau Ying Kit are standing for re-election.  \n   • The Nomination Committee confirmed their independence and satisfactory performance, with Wang Qing’s tenure exceeding nine years requiring a separate vote.\n3. Dividend Proposal  \n   • A final dividend of HK0.167 cents per share (total HK$3.40 million) for FY2025 is recommended. Key dates:  \n     – Ex-dividend date: 19 May 2026  \n     – Record date: 26 May 2026  \n     – Payment date: on or around 4 June 2026\n4. Key Timetable for Shareholders  \n   • Transfer books close 12–15 May 2026 to determine AGM voting eligibility; deadline for lodging transfers is 11 May 2026 at 16:30.  \n   • Books close again 21–26 May 2026 for dividend entitlement; transfer deadline is 20 May 2026 at 16:30.  \n   • Proxy forms must reach Computershare Hong Kong Investor Services by 13 May 2026 at 10:00.\nAll AGM resolutions will be decided by poll in accordance with Hong Kong Listing Rules.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121220588","isCrawlerRequest":true}